AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 APR 11 - (NewsRx.com & NewsRx.net) -- A commonly prescribed medication for treating endometriosis appears to elevate the risk of ovarian cancer, according to findings presented by a University of Pittsburgh Graduate School of Public Health (GSPH) researcher at the 33rd annual meeting of the Society of Gynecologic Oncologists in Miami.
In the study, women taking danazol, a synthetic version of the male hormone androgen, were nearly three times more likely to develop ovarian cancer than were women taking leuprolide, an antiandrogenic, gonadotropin-releasing hormone agonist. Both drugs are used to treat endometriosis, a painful disease in which pieces of uterine tissue migrate to other parts of the body.
"Our previous studies have found that women with endometriosis are already at a 50% increased risk for ovarian cancer, and treating them with danazol appears to further increase their risk. This new result, even though it is preliminary, may factor into the equation when clinicians and their patients with endometriosis are deciding on the best treatment," said presenter Roberta B. Ness, MD, MPH, associate professor of epidemiology at the GSPH and director of the school's Epidemiology of Women's Health Program.
The study analyzed pooled data from two case-control studies that ...